Marinomed licenses Kahalalide F analogs
Spanish drugmaker PharmaMar has licensed analogs of Kahalalide F for uses outside of oncology and neurology to German firm Marinomed Biotechnologie GmbH.
The novel depsipeptide is derived from the Hawaiian sea slug Elysia rufesceus. In preclinical assays performed by Marinomed, certain synthetic analogs of Kahalalide F have shown a favorable activity profile.
As part of the agreement, PharmaMar will collaborate with Marinomed in identifying and synthesizing the most suitable drug candidates and will retain all rights to Kahalalide F analogs for the treatment of cancer and central nervous systems disorders together with all rights on Kahalalide F itself and two of its related analogs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze